AIM ImmunoTech

Moat components and durability assessment: Intangible assets (35/100): AIM owns method‑of‑use and combination patents covering Ampligen with checkpoint inhibitors in the US, Japan and the Netherlands out to 2039, and long‑COVID IP in Europe/UK to 2041. Orphan designations exist in pancreatic cancer.

These protections are real but relatively narrow and depend on future clinical validation and enforceability of method claims. Weight 35%. Switching costs (10/100): With no approved product, there are no embedded workflows or switching frictions; future oncology adoption would be evidence driven. Weight 25%.

Network effects (0/100): No two‑sided platform or data network benefits. Weight 15%. Cost advantages (5/100): As a single‑asset clinical program, AIM lacks scale manufacturing or distribution benefits; CMO sourcing is standard. Weight 15%.

Efficient scale (10/100): Certain orphan oncology niches can display efficient‑scale traits, but this only materializes post‑approval and guideline adoption. Weight 10%. Weighted overall moat is weak given the absence of commercial entrenchment and the need for decisive Phase 3 data to underpin any durable advantage.

Today there is no realized pricing power because AIM has no marketed products. In a successful orphan oncology scenario, list pricing could be high relative to standard chemotherapy, but actual pricing latitude will be constrained by competition and real‑world outcomes.

The competitive bar rose with the August 26, 2026 FDA approval of daraxonrasib for previously treated metastatic pancreatic adenocarcinoma, which could narrow room for premium pricing unless Ampligen combinations show clear additive benefit. Score reflects hypothetical but unproven pricing ability.

AIM lacks recurring revenue and its outlook is binary around an exploratory, single‑center Phase 2 trial (DURIPANC) aiming to assess clinical benefit rate at six months post‑initiation. Timelines are well signposted, but outcome predictability is low, external control benchmarks are shifting, and any subsequent Phase 3 path is unproven.

Approval of daraxonrasib changes the standard of care context and may shift trial designs and payer expectations. Overall visibility into multi‑year cash generation is minimal.

Liquidity at June 30, 2026 totaled about 10.0 million dollars in cash, cash equivalents and marketable investments against total liabilities of roughly 5.0 million dollars and a current portion of notes payable of about 3.6 million dollars.

Net cash outflow from operating activities for the first half of 2026 was approximately 7.3 million dollars, implying short runway without additional capital. The company again disclosed substantial doubt about its ability to continue as a going concern.

Equity issuance and warrant exercises have been the primary financing levers; an ATM facility was terminated in August 2026. Debt is present and near‑term maturities increase risk.

Capital allocation has relied on serial equity offerings, rights offerings, warrant inducements and short‑term notes, resulting in major dilution and shareholder overhang.

Shares outstanding rose from about 3.1 million at year‑end 2025 to 29.0 million by June 30, 2026, and management recorded extensive warrant activity, including inducements and new classes. Use of proceeds is focused on R&D and overhead, appropriate for a clinical company, but funding costs and structures are shareholder‑unfriendly.

No evidence of disciplined repurchases or durable, low‑cost capital.

Thomas K.

Equels remains CEO, visible through frequent communications and a ‘CEO Corner.’ While the team executed on DURIPANC enrollment and NYSE American compliance was regained in June 2026, the long history of development without approvals, persistent going‑concern warnings, heavy dilution and dependence on promotional financing detract from perceived execution quality.

Governance shows standard SEC compliance, but shareholder alignment is questionable given repeated capital raises.